According to 2014 statistics, the 5-year survival rate of thyroid cancer in China is only 67.5%, while in the United States as high as 98.2%. The diagnosis and treatment ability in the top tier tertiary hospitals in China is comparable to that of modern countries. The gap is at the grassroot level. The Thyroid Cancer Postoperative Intelligent Management System empowers lower level healthcare facilities in managing and following up postoperative patients of thyroid cancer to improve the survival rate.
Based on the 2012 Guidelines of Diagnosis and Treatment of Differentiated Thyroid Cancer, our system classifies patients into different rehabilitation clinical management paths according to different pathological types of thyroid cancer. This cloud platform, an AI-driving tool, is easy to use for both patients and doctors to guide the management, treatment and intervention of postoperative patients with thyroid cancer more effectively to help patients reduce the risk of cancer recurrence, improve postoperative survival and effective recovery.
It has been a challenge to track thyroid cancer postoperative data. Our Thyroid Cancer Postoperative Intelligent Management System ensures the completeness of treatment data. By using our system, doctors have the access to patients' full medical history any time at any place. This also provides essential support to academic research in addition to clinic treatment.
Our system provides an easier way for doctors to provide telemedicine and remote healthcare services. The cross-regional, full-course, and combination of virtuality and reality healthcare services enables patient-doctor communication any time at any place.
In response to the higher level of rehabilitation needs of some postoperative patients, our system has specially developed a module for value-added services. Patients can purchase long-term management services from doctors, and doctors can make full use of fragmented time to obtain reasonable income.